NES ZIONA, Israel--(BUSINESS WIRE)--OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today the launch of NBM-200MP, a multi-parameter sensor for non-invasive continuous hemoglobin, low signal oximetry and pulse rate measurements.
Business Wire - NBM-200MP - multi-parameter sensor for non-invasive continuous hemoglobin, low signal oximetry and pulse rate measurements (Photo: Business Wire).
The launch event will take place at the 29th International Symposium on Intensive Care and Emergency Medicine, on March 26 at Brussels, Belgium. Professor Pierre Singer, MD, Head of the Intensive Care Department, Rabin Medical Center, Petah-Tikva, Israel will be chairing a symposium introducing the product and presenting new data indicating that OrSense’s non-invasive continuous monitoring system accurately measures levels of oxygen saturation, hemoglobin and glucose in an intensive care unit.
Hemoglobin (Hb) level, a parameter which indicates hemorrhage or anemia, is a key measurement in hospitals and outpatient wards. However, current hemoglobin measurements are invasive, time consuming, labor intensive and costly. NBM-200MP offers a unique, breakthrough non-invasive solution for accurate continuous and spot Hb measurements. It is useful for hematocrit/hemoglobin determination, hidden blood loss monitoring and for anemia screening. The device is well suited for use in a variety of clinical environments, including perioperative and critical care, emergency medicine, blood donation facilities, women’s health, primary care physician’s office and homecare.
Pulse oximetry has become a standard of care in the operating and recovery rooms, intensive care units and emergency services, yet it has been known to provide erroneous oxygen saturation readings in states of low perfusion, low cardiac output and/or low blood flow. The NBM-200MP system offers for the first time a non-invasive, continuous and accurate measurement of oxygen saturation in states of hypovolemia, hypothermia and vasoconstriction or during open heart surgery, as well as during regular perfusion.
NBM-200MP operates via a ring-shaped sensor that is fitted on the patient’s finger and applies a gentle pressure, temporarily occluding the blood flow. During the occlusion optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the patient’s blood constituent, while greatly improving patient comfort, eliminating infection risk, and providing the caregiver with superior accuracy and immediate results.
“We are proud to introduce NBM-200MP, a truly revolutionary solution for non-invasive measurements of multiple blood parameters,” said Shimon Eckhouse, Ph.D., Chairman of OrSense. “The medical world is constantly striving towards non-invasive monitoring and diagnostic solutions, and our technology propels us another step forward towards this goal in both hospital and home care.”
“Our novel non-invasive oximetry and hemoglobin monitor is expected to enhance the quality of treatment and reduce cost of operation in multiple hospital wards, with particular emphasis on the ICU, OR and ER. NBM-200MP addresses markets that represent annual revenue opportunities of over $2 billion,” added Lior Ma’ayan, CEO of OrSense. “I would like to take this opportunity to thank and congratulate our staff of scientists, engineers and clinicians for their ingenuity, enthusiasm and perseverance. This is a significant moment for all of us.”
About OrSense
OrSense is a medical device company developing non-invasive monitoring systems for measurements of oxygen saturation, hemoglobin, glucose and other blood parameters. The Company’s flagship product is the NBM-200MP, a multi-parameter non-invasive continuous blood oximetry and hemoglobin monitor for use in hospitals. OrSense’s non-invasive hemoglobin/hematocrit monitor was granted the CE approval and was tested on over 4,000 patients at 15 sites in the U.S. and Europe. The Company’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. OrSense’s CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s corporate website at www.orsense.com.
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5921133 Contact:
OrSense Ltd. Tsipi Haitovsky, +972-52-598-9892 Media Liaison tsipi@orsense.com
